Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

References

• Kewalramani T, Zelenetz AD, Nimer SD, et al Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991;9:423–431.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645–652.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, et al Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Gordon LI, et al Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003;21:1263–1270.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918–3928.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Haperen VRV. 2′2′-Difluorodeoxycytidine (gemcitabine) incorporation into DNA and RNA of tumor cell lines. Biochem Pharmacol 1993;46:762–766.
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, et al Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000;18:2615–2619.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Baliva G, Magagnoli M, et al Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603–2606.
   PubMed Web of Science ®Google Scholar
• Fossa A, Santoro A, Hiddemann W, et al Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786–3792.
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, et al Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762–1767.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol 2006;17(Suppl. 4):iv18–iv24.
   PubMedGoogle Scholar
• Crump M, Baetz T, Couban S, et al Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:1835–1842.
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, et al Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363–1368.
   PubMed Web of Science ®Google Scholar
• Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol 2009;27:1456–1461.
   PubMed Web of Science ®Google Scholar
• Iaffaioli RV, Tortoriello A, Facchini G, et al Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 1999;17:921–926.
   PubMed Web of Science ®Google Scholar
• Gandara DR, Lau DH, Lara PN Jr, Edelman MJ. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Huntingt) 2000;14:26–30.
   PubMedGoogle Scholar
• Yardley DA, Burris HA 3rd, Simons L, et al A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 2008;8:425–431.
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699–4707.
   PubMed Web of Science ®Google Scholar
• Ng EW, Sandler AB, Robinson L, Einhorn LH. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. Am J Clin Oncol 1999;22:550–553.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification–from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000;11(Suppl. 1):3–10.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al editors. Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008
   Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Smardova L, Engert A, Haverkamp H, et al Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005;46:1017–1022.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–39.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Gutierrez A, Palacios A, et al Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007;48:2172–2178.
   PubMed Web of Science ®Google Scholar
• Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003;2:597–607.
   PubMedGoogle Scholar